ArticleUrologia internationalis2025
The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A Single-Center Experience.
Article in Urologia internationalis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of this study was to determine the impact of diabetes and antidiabetic medications on referral and pathological outcomes in uro-oncology cases. We report preliminary results from a single-center study.
methodsWe retrospectively collected data from 781 patients treated between 2018 and 2023 for radical prostatectomy (RP) for prostate cancer (PCa), radical cystectomy (RC) for bladder cancer, radical nephroureterectomy for upper tract urothelial carcinoma, partial nephrectomy and radical nephrectomy (RN) for renal cell carcinoma (RCC). A total of 617 (79%) patients were nondiabetics, and 164 (21%) were diabetics. Patient data were assessed for differences between diabetics and nondiabetics.
resultsAll diabetic patients had a significantly higher BMI than nondiabetic patients (p < 0.05 for PCa and p = 0.006 for RC, respectively). In diabetic patients with PCa, a lower proportion of ISUP grade 3 and 5 PCa was seen (p = 0.047). In diabetic RCC patients on antidiabetic medication, there was a significantly higher incidence of recurrence rates after RN (p = 0.015). Penile cancer was diagnosed in diabetic patients at an older age (p = 0.019).
conclusionSignificantly, higher BMI was observed for RP and RC in diabetic patients, as well as for RCC after RN. Diabetics showed a significantly higher occurrence of recurrence for RCC after RN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.